Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2015

View Archived Issues

Preliminary data reported from phase I/IIa study of third-generation CAR T cells targeting CD19

SVN-2B peptide vaccination shows promise for gastrointestinal cancer

Phase I clinical trial shows promising results for TIL 1383I transduced T cells

JCR and Sumitomo Dainippon Pharma enter feasibility agreement in psychiatry and neurology

Avalon Ventures and GSK launch new companies Adrenergics, CadheRx and Calporta

Queensland Emory Drug Discovery Initiative announced

Once-weekly LAPSInsulin Combo shows better glycemic control, reduced side effects

Eppin Pharma receives NIH grant to develop non-hormonal male contraceptive

FDA approves Zomig Nasal Spray for patients aged 12-17 years

Novartis to develop inhaled indacaterol/glycopyrronium bromide/mometasone furoate

Teva releases topline data from pivotal study of SD-809 for tardive dyskinesia

FDA clears IND for U.S. study of GTL-001 HPV therapeutic vaccine candidate

Novel gene therapy shows promising results in mouse models of Friedreich's ataxia

Fagron licenses U.S. rights to OMS-103 from Omeros

OncoSec Medical starts phase II study of ImmunoPulse in HNSCC

AveXis licenses rights to AskBio's AAV Duplex vector technology for use in SMA gene therapy

Admune Therapeutics starts phase I trial of hetIL-15 in metastatic cancers

Aimmune Therapeutics receives FDA breakthrough therapy designation for AR-101

Roche and Genentech introduce BTK inhibitors

Lead Pharma patents RORgamma modulators

Sichuan Haisco discloses FXa inhibitors

Jiangsu Aosaikang discloses EGFR inhibitors

Beijing JenKem presents EGFR inhibitors for AD

World Sickle Cell Day: LentiGlobin gene therapy continues to impress in clinical study

Allergan to acquire Kythera Biopharmaceuticals

Tribute Pharmaceuticals acquires Medical Futures

Akashi Therapeutics reports data on HT-100 in patients with DMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...